An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. [electronic resource]
Producer: 20070926Description: 2542-6 p. digitalISSN:- 1042-8194
- Aged
- Alemtuzumab
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- administration & dosage
- Antiviral Agents -- therapeutic use
- Cytomegalovirus Infections -- complications
- Female
- Ganciclovir -- administration & dosage
- Humans
- Immune System -- pathology
- Infusions, Intravenous
- Leukemia, Lymphocytic, Chronic, B-Cell -- complications
- Male
- Middle Aged
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.